摘要
目的探讨尤瑞克林与胞二磷胆碱联合治疗急性前循环脑梗死的疗效和安全性。方法将64例急性前循环脑梗死患者在同时给予常规治疗的基础上随机分为单用胞二磷胆碱组和尤瑞克林与胞二磷胆碱联合治疗组,静脉滴注共14 d,观察两组患者治疗前和治疗后14 d神经功能缺损程度评分(neurological deficiency score,NDS)及日常生活活动量表(BI指数)评分的变化及不良反应。结果治疗后联合治疗组和单用胞二磷胆碱组患者NDS及日常生活活动量表评分与治疗前相比均有显著改善(P<0.01),联合治疗组改善程度与对照组相比差异有极显著性(P<0.01)。两组均未发现明显不良反应。结论尤瑞克林联合胞二磷胆碱治疗急性前循环脑梗死疗效优于单药治疗,且安全性好。
Aim To investigate the effect and safety of urinary kallidinogenase combined with citicoline in the treatment of acute carotisal cerebral infarction. Methods 64 cases with acute carotisal cerebral infarction were divided into two groups based on routine treatment randomly：citicoline group （n = 32 ）and urinary, kallidinogenase combined with citicoline group （n = 32）. citicoline group was treated with citicoline for 14 days and combined group was treated with citicoline 0. 175 g · d^-1 and urinary kallidinogenase 0.15PNA for 14 days. The neurological deficit scores （NDS） , BI index and adverse reactions were evaluated before and after the treatment, respectively. Results After the treatment, the scores of NDS and BI index were significantly decreased in two groups than those before the treatment （P 〈 0. 01 ） , and kallidinogenase combined with eitieoline group was much better than citicoline group. There was no obvious adverse reaction in two groups. Conclusion Kallidinogenase combined with citicoline shows better clinic effect and no more hemorrhagic risk than citicoline in the therapy of acute earotisal cerebral infarction.
出处
《安徽医药》
CAS
2009年第1期72-74,共3页
Anhui Medical and Pharmaceutical Journal
关键词
急性脑梗死
胞二磷胆碱
联合治疗
acute cerebral infarction
citicoline
combined treatment
